Cargando…

Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis

The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitag, Julien, Wickham, James, Shah, Kiran, Tenen, Abi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398814/
https://www.ncbi.nlm.nih.gov/pubmed/30819682
http://dx.doi.org/10.1136/bcr-2018-227865
_version_ 1783399646302830592
author Freitag, Julien
Wickham, James
Shah, Kiran
Tenen, Abi
author_facet Freitag, Julien
Wickham, James
Shah, Kiran
Tenen, Abi
author_sort Freitag, Julien
collection PubMed
description The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336).
format Online
Article
Text
id pubmed-6398814
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-63988142019-03-21 Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis Freitag, Julien Wickham, James Shah, Kiran Tenen, Abi BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) The aim of this case report is to evaluate the efficacy of mesenchymal stem cell (MSC) therapy in the treatment of small joint osteoarthritis (OA). Acromio-clavicular (AC) joint OA is an under-diagnosed and yet frequent source of shoulder pain. MSCs have shown evidence of benefit in the treatment of knee OA. This is the first report to describe the use of MSC therapy in OA of the upper limb. A 43-year-old patient presents with painful AC joint OA and undergoes MSC therapy. The patient reported pain and functional improvement as assessed by the Disability of Arm, Shoulder and Hand Score and Numeric Pain Rating Scale. Imaging at 12 months showed structural improvement with reduction in subchondral oedema, synovitis and subchondral cysts. This case is the first to show the benefit of MSC therapy in the treatment of small joint arthropathy and also of the upper limb. Trial registration number: Australian New Zealand Clinical Trials Registry (ACTRN12617000638336). BMJ Publishing Group 2019-02-27 /pmc/articles/PMC6398814/ /pubmed/30819682 http://dx.doi.org/10.1136/bcr-2018-227865 Text en © BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Freitag, Julien
Wickham, James
Shah, Kiran
Tenen, Abi
Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
title Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
title_full Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
title_fullStr Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
title_full_unstemmed Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
title_short Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
title_sort effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
topic Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398814/
https://www.ncbi.nlm.nih.gov/pubmed/30819682
http://dx.doi.org/10.1136/bcr-2018-227865
work_keys_str_mv AT freitagjulien effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis
AT wickhamjames effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis
AT shahkiran effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis
AT tenenabi effectofautologousadiposederivedmesenchymalstemcelltherapyinthetreatmentofacromioclavicularjointosteoarthritis